Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 2, 2012, Pages 306-312

  Kim, Yu Jin ^a   Cho, Hyun Chin ^a   Sinn, Dong Hyun ^a   Gwak, Geum Youn ^a   Choi, Moon Seok ^a   Koh, Kwang Cheol ^a   Paik, Seung Woon ^a   Yoo, Byung Chul ^a   Lee, Joon Hyeok ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Adefovir dipivoxil; Chronic hepatitis B; Glomerular filtration rate; Renal insufficiency

Indexed keywords

ADEFOVIR DIPIVOXIL; CONTRAST MEDIUM; LAMIVUDINE;

ADOLESCENT; ADULT; AGED; ARTICLE; COMPENSATED CIRRHOSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HEPATITIS B; HUMAN; INCIDENCE; KIDNEY FUNCTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORBIDITY; NEPHROTOXICITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION;

EID: 84862957095     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06852.x     Document Type: Article

References (20)

1. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
2. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J. Hepatol. 2009; 50: 227-42.
3. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009; 137: 1593-608.
4. Danta M, Dusheiko G. Adefovir dipivoxil: review of a novel acyclic nucleoside analogue. Int. J. Clin. Pract. 2004; 58: 877-86.
5. Izzedine H, Hulot JS, Launay-Vacher V et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int. 2004; 66: 1153-8.
6. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5years. Gastroenterology 2006; 131: 1743-51.
7. Marcellin P, Chang TT, Lim SG et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008; 48: 750-8.
8. Schiff E, Lai CL, Hadziyannis S et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl. 2007; 13: 349-60.
9. Lampertico P, Viganò M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133: 1445-51.
10. Kim HJ, Park JH, Park DI et al. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy. J. Gastroenterol. Hepatol. 2010; 25: 1374-80.
11. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis. 2002; 39: S1-266.
12. Tamori A, Enomoto M, Kobayashi S et al. Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus. J. Viral Hepat. 2010; 17: 123-9.
13. Vigano M, Lampertico P, Iavarone M, Tontini GE, Facchetti F, Colombo M. High risk of renal impairment and arterial hypertension during long-term adefovir and lamivudine combination therapy in patients with lamivudine-resistant chronic hepatitis B. Hepatology 2008; 48 (Suppl. 1): 897A.
14. Ha NB, Ha NB, Garcia RT et al. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 2009; 50: 727-34.
15. Izzedine H, Launay-Vacher V, Deray G. Antiviral drug-induced nephrotoxicity. Am. J. Kidney Dis. 2005; 45: 804-17.
16. Dienstag JL. Benefits and risks of nucleoside analog therapy for hepatitis B. Hepatology 2008; 49: S112-21.
17. Khungar V, Han SH. A systematic review of side effects of nucleoside and nucleotide drugs used for treatment of chronic hepatitis B. Curr. Hepat. Rep. 2010; 9: 75-90.
18. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009; 49: S185-95.
19. Francoz C, Glotz D, Moreau R, Durand F. The evaluation of renal function and disease in patients with cirrhosis. J. Hepatol. 2010; 52: 605-13.
20. Cholongitas E, Shusang V, Marelli L et al. Review article: renal function assessment in cirrhosis-difficulties and alternative measurements. Aliment. Pharmacol. Ther. 2007; 26: 969-78.